LDLR and cancer: As a proof-of-concept, we generated LIPTACs to degrade EGFR,a receptor tyrosine kinase that plays a critical role in the developmentand progression of various types of cancers., The therapeutic anti-EGFR Cetuximab (Ctx) and anti-LDLR antibody(142F1 or 142F6) were fused to heterodimeric Fc domains respectively, with T350V/L351Y/F405A/Y407V mutations in chainA and T350V/T366L/K392L/T394W mutations in chain B. To eliminate Fc-effectorfunction for macrophage and NK cell recruitment, we introduced theL234A/L235A/P329G mutations (LALAPG) inboth Fc chains.